Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N.M. Reina Marfil, E. Ortega Sáenz de Tejada, L. López López, A.M. Franco Torres, J.L. Velasco Garrido, C. Fernández Aguirre, M.V. Hidalgo Sanjuán (Malaga, Spain). Tuberculosis and tumor necrosis factor alpha antagonist: Our experience. Eur Respir J 2012; 40: Suppl. 56, 2611

Member's Comments

No comment yet.

Related content which might interest you: Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015 The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010 Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 Tumour necrosis factor gene polymorphisms and childhood wheezing Source: Eur Respir J 2005; 26: 637-646 Year: 2005 Effects of zinc on the interleukin-1 and tumor necrosis factor in experimental silicosis Source: Eur Respir J 2002; 20: Suppl. 38, 517s Year: 2002 Tumour necrosis factor and lymphotoxin A polymorphisms: a relationship with COPD and its progression? Source: Eur Respir J 2007; 29: 8-10 Year: 2007 Role of tumor necrosis factor alpha in hepatopulmonary syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 562s Year: 2004 Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Expression levels of membrane-bound tumor necrosis factor alpha receptors in active tuberculosis and healthy individuals Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Vascular endothelial growth factor and tumor necrosis factor gene polymorphisms in Turkish patients with sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 353s Year: 2006 Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers Source: Eur Respir J 2007; 29: 34-41 Year: 2007 The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006 Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial Source: Eur Respir J 2014; 43: 295-298 Year: 2004 The haplotypes of interleukin 10 but not that of tumour necrosis factor alpha/lymphotoxin alpha and interleukin 1 cluster are associated with susceptibility for COPD Source: Eur Respir J 2005; 26: Suppl. 49, 105s Year: 2005